25539-27-9

Basic information

• Product Name: 4-CHLOROCARBONYL-PIPERAZINE-1-CARBOXYLIC ACID BENZYL ESTER
• Synonyms: 4-CHLOROCARBONYL-PIPERAZINE-1-CARBOXYLIC ACID BENZYL ESTER;4-Cbz-piperazine-1-carbonyl Chloride
• CAS NO: 25539-27-9
• Molecular Formula: C₁₃H₁₅ClN₂O₃
• Molecular Weight: 282.72
• Mol File: 25539-27-9.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 203-208 °C(Press: 1.3 Torr)
• Appearance: /
• Density: 1.327±0.06 g/cm3(Predicted)
• PKA: -0.55±0.70(Predicted)
• CAS DataBase Reference: 4-CHLOROCARBONYL-PIPERAZINE-1-CARBOXYLIC ACID BENZYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLOROCARBONYL-PIPERAZINE-1-CARBOXYLIC ACID BENZYL ESTER(25539-27-9)
• EPA Substance Registry System: 4-CHLOROCARBONYL-PIPERAZINE-1-CARBOXYLIC ACID BENZYL ESTER(25539-27-9)

Safety Data

• Hazardous Substances Data: 25539-27-9(Hazardous Substances Data)

Upstream product

• 75-44-5 phosgene 
• 31166-44-6 phenylmethyl 1-piperazinecarboxylate 
• 75-35-4 1,1-Dichloroethylene 
• 503-38-8 trichloromethyl chloroformate 

Downstream Products

• 635732-24-0 3-amino-6-((S)-3-hydroxy-4-methanesulfonylamino-piperidin-1-yl)-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide 
• 1326282-06-7 benzyl 4-((3-chloropyrazin-2-yl)methylcarbamoyl)piperazine-1-carboxylate 
• 1097834-07-5 benzyl 4-((2-(tert-butoxycarbonylamino)ethyl)(4-chlorobenzyl)carbamoyl)piperazine-1-carboxylate 

Relevant articles and documents

8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS

The present invention provides 8-methyl-1 -phenyl-imidazo[1,5-a]pyrazine derivatives according to formula I or pharmaceutically acceptable salts thereof. The compounds of the current invention show inhibitory activity against Lck and can be used for the treatment of Lck-mediated diseases or Lck-mediated conditions such as inflammatory disorders.

SUBSTITUTED 3-AMINO-THIENO[2,3-b]PYRIDINE-2-CARBOXYLIC ACID AMIDE COMPOUNDS AND PROCESSES FOR PREPARING AND THEIR USES

Disclosed are compounds of formula (I), wherein R1 and R2 are defined herein, which are useful as inhibitors of the kinase activity of the IκB kinase (IKK) complex. The compounds are therefore useful in the treatment of IKK mediated diseases including autoimmune diseases inflammatory diseases and cancer. Also disclosed are pharmaceutical compositions comprising these compounds and processes for preparing these compounds.